Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RGNX – REGENXBIO Inc.

REGENXBIO Inc.
RGNX
$8.39
Name : REGENXBIO Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $422,761,216.00
EPSttm : -3.09
finviz dynamic chart for RGNX
REGENXBIO Inc.
$8.39
4.11%
$0.36

Float Short %

12.07

Margin Of Safety %

Put/Call OI Ratio

0.53

EPS Next Q Diff

0.96

EPS Last/This Y

4.82

EPS This/Next Y

-1.75

Price

8.38

Target Price

33.15

Analyst Recom

1.38

Performance Q

6.07

Relative Volume

1.03

Beta

1.08

Ticker: RGNX




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02RGNX10.330.350.034238
2025-06-03RGNX10.140.340.064391
2025-06-04RGNX10.090.340.004459
2025-06-05RGNX8.360.340.424434
2025-06-06RGNX9.590.340.024794
2025-06-09RGNX9.510.290.185347
2025-06-10RGNX9.810.290.015408
2025-06-11RGNX10.20.270.005626
2025-06-12RGNX10.220.280.005605
2025-06-13RGNX9.260.270.485605
2025-06-16RGNX9.160.280.035665
2025-06-17RGNX8.640.300.015496
2025-06-18RGNX8.550.300.105458
2025-06-20RGNX8.430.304.675510
2025-06-23RGNX7.840.4425.143779
2025-06-24RGNX8.570.480.043913
2025-06-25RGNX8.540.4717.334007
2025-06-26RGNX8.760.540.004216
2025-06-27RGNX8.380.533.094239
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02RGNX10.35-0.4246.10.23
2025-06-03RGNX10.13-0.4219.20.23
2025-06-04RGNX10.09-0.4221.40.23
2025-06-05RGNX8.36-0.4199.20.23
2025-06-06RGNX9.60-0.4244.80.23
2025-06-09RGNX9.53-0.4220.90.23
2025-06-10RGNX9.81-0.4226.00.23
2025-06-11RGNX10.21-0.4227.50.23
2025-06-12RGNX10.20-0.4222.00.23
2025-06-13RGNX9.26-0.4209.70.23
2025-06-16RGNX9.17-0.4220.20.23
2025-06-17RGNX8.64-0.4213.80.23
2025-06-18RGNX8.57-0.4220.40.23
2025-06-20RGNX8.43-0.4219.30.23
2025-06-23RGNX7.85-0.4211.40.23
2025-06-24RGNX8.56-0.4236.20.23
2025-06-25RGNX8.53-0.4221.40.23
2025-06-26RGNX8.77-0.4226.10.23
2025-06-27RGNX8.38-0.4215.60.23
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02RGNX-0.442.3113.85
2025-06-03RGNX-0.442.3113.85
2025-06-04RGNX-0.442.3113.85
2025-06-05RGNX-0.442.3113.85
2025-06-06RGNX-0.442.3113.85
2025-06-09RGNX-0.442.3313.87
2025-06-10RGNX-0.442.3313.87
2025-06-11RGNX-0.442.3313.25
2025-06-12RGNX-0.442.3313.25
2025-06-13RGNX-0.442.3313.25
2025-06-16RGNX-0.442.3413.25
2025-06-17RGNX-0.442.3413.25
2025-06-18RGNX-0.432.3413.19
2025-06-20RGNX-0.432.3413.19
2025-06-23RGNX-0.432.3413.19
2025-06-24RGNX-0.432.3413.19
2025-06-25RGNX-0.432.3413.19
2025-06-26RGNX-0.432.3412.07
2025-06-27RGNX-0.432.3412.07
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.12

Avg. EPS Est. Current Quarter

-1.05

Avg. EPS Est. Next Quarter

1.08

Insider Transactions

-0.43

Institutional Transactions

2.34

Beta

1.08

Average Sales Estimate Current Quarter

40

Average Sales Estimate Next Quarter

110

Fair Value

Quality Score

44

Growth Score

34

Sentiment Score

34

Actual DrawDown %

83.3

Max Drawdown 5-Year %

-89.4

Target Price

33.15

P/E

Forward P/E

PEG

P/S

2.7

P/B

1.53

P/Free Cash Flow

EPS

-3.14

Average EPS Est. Cur. Y​

0.23

EPS Next Y. (Est.)

-1.52

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-100.62

Relative Volume

1.03

Return on Equity vs Sector %

-81.4

Return on Equity vs Industry %

-63.6

EPS 1 7Days Diff

EPS 1 30Days Diff

1.21

EBIT Estimation

215.6
REGENXBIO Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading